Funded Research
Since 2010, the Snowdome Foundation has committed a total of $53 million towards cutting-edge blood cancer research.
This funding has supported 67 research projects and facilitated the creation of over 98 research positions.
Snowdome is the leading not-for-profit focused exclusively on translational research, where scientific findings are used to
advance the development of innovative diagnostic tools and treatments. We have a keen interest in research
that accelerates next-generation treatments and advances precision therapy including genomic testing,
targeted therapies and immune therapies. We fund both research and clinical trials.
Grants
Through the incredible generosity of our philanthropic donors and partners, the Snowdome Foundation can provide Australia’s best clinicians and researchers with much-needed funding to support their work.
In 2023, Snowdome awarded the following grants to exceptional researchers pursuing innovative approaches to blood cancer research and treatments.
- Dr Patrick Connerty: Bob and Jean Cannon Travel Grant
- Professor Mark Dawson: Molecular determinants of immune evasion to CAR-T cells at single clone resolution
- Dr Jennifer Devlin: Bob and Jean Cannon Travel Grant
- Associate Professor Michael Dickinson: Optimising immunotherapy for aggressive lymphoma
- Associate Professor Jane Oliaro: Developing next-generation armoured CAR-T cells for the treatment of multiple myeloma
- Dr Matthew Rees: B-cell Maturation Antigen Resistance in Multiple Myeloma
- Associate Professor David Ross: HSANZ Snowdome Foundation-Mid-Career Award (2023)
